Healthcare - Biotechnology - NASDAQ - US
$ 8.69
-3.55 %
$ 1.01 B
Market Cap
-6.12
P/E
CASH FLOW STATEMENT
-55.2 M
OPERATING CASH FLOW
13.9 M
INVESTING CASH FLOW
74.5 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Applied Therapeutics, Inc.
| Net Income | -120 M |
| Depreciation & Amortization | 354 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 7.36 M |
| Change in Working Capital | -1.44 M |
| Others | 59.7 M |
| Free Cash Flow | -55.2 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (119.8) | (82.5) | (105.6) | (94.0) | (45.5) | (16.5) | (4.3) |
| Depreciation & Amortization | 0.4 | 0.4 | 0.4 | 0.4 | 23 K | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 2.6 | 0 | 0 | 0 |
| Stock Based Compensation | 7.4 | 9.6 | 11.2 | 8.0 | 6.2 | 0.3 | 32 K |
| Other Operating Activities | 58.3 | 3.7 | (0.4) | (0.4) | (0.2) | 3.0 | 0.5 |
| Change in Working Capital | (1.4) | (8.8) | 3.7 | 5.2 | 3.2 | 2.1 | 0.6 |
| Cash From Operations | (55.2) | (78.1) | (90.7) | (78.2) | (36.3) | (11.2) | (3.2) |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Items | 13.9 | 13.2 | 12.4 | (19.5) | (20.0) | 0 | 0 |
| Cash From Investing Activities | 13.9 | 13.2 | 12.4 | (19.5) | (20.0) | 0 | 0 |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | (1.9) | (3.3) | (4.7) | (2.1) | 0 | 5.6 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 11.9 | 3.2 | 5.0 | 4.3 | 6.0 | 21.1 | 6.5 |
| Cash From Financing Activities | 74.5 | 27.7 | 74.7 | 136.3 | 56.4 | 26.7 | 6.5 |
| CHANGE IN CASH | |||||||
| Net Change In Cash | 33.2 | (37.2) | (3.6) | 38.6 | 0.1 | 15.5 | 3.3 |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (55.2) | (78.1) | (90.7) | (78.2) | (36.3) | (11.2) | (3.2) |